Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta‐analysis
Clinical Endocrinology · 2024-04 · 100 (4) · 379-388
DOI: 10.1111/cen.15027 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Endocrinology, online erschienen am 13.02.2024. Verfasst von Jiayi Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Quinolines, Thyroid Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Translational medicine fund of West China Hospital, West China Nursing Discipline Development Special Fund Project, Sichuan Province Science and Technology Support grant and TianFu Laboratory.
Abstract (Originalsprache)
Background
The poor overall prognosis of radioiodine refractory thyroid cancer is an inevitable challenge in managing this disease. A series of trials have demonstrated the antitumor activity of tyrosine kinase inhibitors (TKIs) in radioiodine refractory differentiated thyroid cancer (RAIR‐DTC). However, the available evidence cannot determine the optimal choice of TKI in RAIR‐DTC.
Methods
This study searched PubMed, EMBASE, Cochrane databases, and the ClinicalTrials website. The Cochrane bias risk tool was used to assess the risk of bias, and to evaluate randomized clinical trials (RCT) of RAIR‐DTC patients treated with the TKI system. Outcomes, including progression‐free survival (PFS), overall survival (OS), and adverse events (AEs) were reported.
Results
Seven studies involving 1310 patients with RAIR‐DTC was conducted to compare the PFS and OS of various TKI monotherapies with placebo. The results showed that all TKI monotherapies had a statistically significant benefit in terms of PFS compared with placebo, with lenvatinib demonstrating the greatest benefit (hazard ratio [HR] 0.19, 95% credible interval [CrI] 0.14–0.25). In terms of OS, only apatinib (HR 0.42, 95% CrI 0.18–0.97) and anlotinib (HR 0.36, 95% CrI 0.18–0.73) showed statistically significant benefits compared with placebo. TKIs also had a higher incidence of AEs of grade 3 or higher compared with placebo. The findings suggest that lenvatinib may be the preferred TKI for the treatment of RAIR‐DTC, although its high incidence of AEs should be considered. The results also indicate that TKI treatment may be similarly effective in RAIR‐DTC patients with BRAF or RAS mutations and in those with papillary or follicular subtypes of the disease, regardless of prior TKI treatment.
Conclusions
The results of this meta‐analysis suggest that targeted therapy with TKIs may be beneficial for patients with radioiodine‐refractory advanced or metastatic differentiated thyroid cancer. Among the TKIs analyzed, lenvatinib appeared to be the most effective at improving PFS, although it also had the highest incidence of AEs. Further research through direct randomized controlled trials is needed to determine the optimal choice of TKI for treating patients with RAIR‐DTC. This study is beneficial for formulating patients' treatment plans and guides clinicians' decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, P. R. China.
- Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Rehabilitation, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Xingchen Peng
Förderung
- Translational medicine fund of West China Hospital
- West China Nursing Discipline Development Special Fund Project
- Sichuan Province Science and Technology Support grant and TianFu Laboratory
- National Natural Science Foundation of China
- Post-Doctor Research Project, West China Hospital, Sichuan University
- The National Key Research and Development Program of China
Zitieren
APA
Yu, J., Liu, Z., Su, Y., Peng, X., & Xie, Y. (2024). Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta‐analysis. Clinical Endocrinology, 100(4), 379-388. https://doi.org/10.1111/cen.15027
Vancouver
Yu J, Liu Z, Su Y, Peng X, Xie Y. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta‐analysis. Clinical Endocrinology. 2024;100(4):379-388. doi:10.1111/cen.15027
BibTeX
@article{Yu2024,
author = {Yu, Jiayi and Liu, Zheran and Su, Yonglin and Peng, Xingchen and Xie, Yuping},
title = {Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta‐analysis},
journal = {Clinical Endocrinology},
year = {2024},
volume = {100},
number = {4},
pages = {379--388},
doi = {10.1111/cen.15027}
}
EUVIMED